Relapse of postpolycythemia myelofibrosis after allogeneic stem cell transplantation in a polycythemic phase: successful treatment with donor lymphocyte infusion directed by quantitative PCR test for V617F-JAK2 mutation

Benjamini, Ohad; Koren‐Michowitz, Maya; Amariglio, Ninette; Nagler, Arnon; Shimoni, Avichai

doi:10.1038/leu.2008.215

Cited by 19 publications

(13 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3,4 Single case reports about successful donor lymphocyte infusion (DLI) for relapsed patients provided evidence of a graft-versus-myelofibrosis effect. [5][6][7] Here, we report on 17 patients with either myelofibrosis (n ϭ 16) or secondary AML post myelofibrosis (n ϭ 1) and a median age of 52 years (range, 32-63 years) who received DLI from related (n ϭ 5) or unrelated (n ϭ 12) donor, either for clinical relapse (salvage DLI; n ϭ 9) or residual disease monitored by JAK2 mutation level in peripheral blood (preemptive DLI; n ϭ 8). Details are summarized in Table 1.…”

Section: To the Editormentioning

confidence: 99%

JAK2-V617F–triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation

Kröger¹,

Alchalby²,

Klyuchnikov³

et al. 2009

Blood

View full text Add to dashboard Cite

Section: To the Editormentioning

confidence: 99%

JAK2-V617F–triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation

Kröger¹,

Alchalby²,

Klyuchnikov³

et al. 2009

Blood

View full text Add to dashboard Cite

“…The optimal GvHD prophylaxis is unclear (Soiffer et al, 2011). Donor lymphocyte infusions may reverse clinical or JAK2 V617F molecular relapse/persistence Guideline post-HSCT (Byrne et al, 2000;Benjamini et al, 2008;Kröger et al, 2009b).…”

Section: Reduced Intensity Hsctmentioning

confidence: 99%

Guideline for the diagnosis and management of myelofibrosis

et al. 2012

View full text Add to dashboard Cite

SummaryThe guideline group regarding the diagnosis and management of myelofibrosis was selected to be representative of UK-based medical experts, together with a contribution from a single expert from the USA. MEDLINE and EMBASE were searched systematically for publications in English from 1966 until August 2011 using a variety of key words. The writing group produced the draft guideline, which was subsequently revised by consensus of the members of the General Haematology and Haemato-oncology Task Forces of the British Committee for Standards in Haematology (BCSH). The guideline was then reviewed by a sounding board of UK haematologists, the BCSH and the British Society for Haematology Committee and comments incorporated where appropriate. The criteria used to state levels and grades of evidence are as outlined in the Procedure for Guidelines commissioned by the BCSH; the 'GRADE' system was used to score strength and quality of evidence. The objective of this guideline is to provide healthcare professionals with clear guidance on the investigation and management of primary myelofibrosis, as well as post-polycythaemic myelofibrosis (post-PV MF) and post-thrombocythemic myelofibrosis (post-ET MF) in both adult and paediatric patients.

show abstract

“…[7][8][9] Evidence for an immunologically mediated graft-versus-myelofibrosis effect comes from reports in relapsed patients after AHSCT that show a remarkable reduction of bone marrow fibrosis after donor lymphocyte infusion. [10][11][12][13] We here report the outcome of a prospective multicenter phase 2 study in patients with advanced PMF evaluating a dose-reduced conditioning regimen followed by stem cell transplantation from related or unrelated donors.…”

Section: Introductionmentioning

confidence: 99%

Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Kröger

Holler

Kobbe

et al. 2009

Blood

363

399

View full text Add to dashboard Cite

From 2002 to 2007, 103 patients with primary myelofibrosis or postessential thrombocythemia and polycythemia vera myelofibrosis and a median age of 55 years (range, 32-68 years) were included in a prospective multicenter phase 2 trial to determine efficacy of a busulfan (10 mg/kg)/fludarabine (180 mg/m 2 )-based reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation from related (n ‫؍‬ 33) or unrelated donors (n ‫؍‬ 70). All but 2 patients (2%) showed leukocyte and platelet engraftment after a median of 18 and 22 days, respectively. Acute graft-versushost disease grade 2 to 4 occurred in 27% and chronic graft-versus-host disease in 43% of the patients. Cumulative incidence of nonrelapse mortality at 1 year was 16% (95% confidence interval, 9%-23%) and significantly lower for patients with a completely matched donor (12% vs 38%; P ‫؍‬ .003). The cumulative incidence of relapse at 3 years was 22% (95% confidence interval, 13%-31%) and was influenced by Lille risk profile (low, 14%; intermediate, 22%; and high, 34%; P ‫؍‬ .02). The estimated 5-year event-free and overall survival was 51% and 67%, respectively. In a multivariate analysis, age older than 55 years (hazard ratio ‫؍‬ 2.70; P ‫؍‬ .02) and human leukocyte antigenmismatched donor (hazard ratio ‫؍‬ 3.04; P ‫؍‬ .006) remained significant factors for survival. The study was registered at www. clinicaltrials.gov as #NCT 00599547. (Blood. 2009;114:5264-5270)

show abstract

Relapse of postpolycythemia myelofibrosis after allogeneic stem cell transplantation in a polycythemic phase: successful treatment with donor lymphocyte infusion directed by quantitative PCR test for V617F-JAK2 mutation

Cited by 19 publications

References 8 publications

JAK2-V617F–triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation

JAK2-V617F–triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation

Guideline for the diagnosis and management of myelofibrosis

Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Contact Info

Product

Resources

About